Werewolf Therapeutics (HOWL) FCF Margin (2022 - 2024)
Werewolf Therapeutics (HOWL) has disclosed FCF Margin for 3 consecutive years, with 94186.67% as the latest value for Q4 2024.
- On a quarterly basis, FCF Margin fell 9385251.0% to 94186.67% in Q4 2024 year-over-year; TTM through Sep 2025 was 422640.0%, a 42126264.0% decrease, with the full-year FY2024 number at 2957.26%, down 278988.0% from a year prior.
- FCF Margin was 94186.67% for Q4 2024 at Werewolf Therapeutics, down from 1241.82% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 51.98% in Q2 2022 to a low of 94186.67% in Q4 2024.
- A 3-year average of 9886.0% and a median of 269.54% in 2023 define the central range for FCF Margin.
- Peak YoY movement for FCF Margin: soared 19020bps in 2023, then crashed -9385251bps in 2024.
- Werewolf Therapeutics' FCF Margin stood at 170.09% in 2022, then plummeted by -96bps to 334.15% in 2023, then plummeted by -28087bps to 94186.67% in 2024.
- Per Business Quant, the three most recent readings for HOWL's FCF Margin are 94186.67% (Q4 2024), 1241.82% (Q2 2024), and 2076.55% (Q1 2024).